Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-es study

References

• Boarts, J. M., Sledjeski, E. M., Bogart, L. M., & Delahanty, D. L. (2006). The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS and Behavior, 10(3), 253–261. doi:10.1007/s10461-006-9069-7. Retrieved from PM:16482405. doi: 10.1007/s10461-006-9069-7
   PubMed Web of Science ®Google Scholar
• Brouwer, E. S. N. S., & Eron, J. J. (2014). Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral regimen: Evidence of channelling bias in HIV clinical care. Paper presented at the 5th International Aids Society Conference on HIV Pathogenesis Treatment and Prevention, Cape Town, South Africa.
   Google Scholar
• Caro-Murillo, A. M., Castilla, J., Perez-Hoyos, S., Miro, J. M., Podzamczer, D., Rubio, R., … Moreno, S. (2007). Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): metodología y primeros resultados. Enfermedades infecciosas y microbiologia clinica, 25(1), 23–31. doi: 13096749 [pii]. Retrieved from PM:17261243. doi: 10.1157/13096749
   PubMed Web of Science ®Google Scholar
• Carrieri, M. P., Chesney, M. A., Spire, B., Loundou, A., Sobel, A., Lepeu, G., & Moatti, J. P. (2003). Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. International Journal of Behavioral Medicine, 10(1), 1–14. Retrieved from PM:12581944. doi: 10.1207/S15327558IJBM1001_01
   PubMed Web of Science ®Google Scholar
• Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. British Journal of Clinical Pharmacology, 51(3), 213–217. doi: bcp342 [pii]. Retrieved from PM:11298066. doi: 10.1046/j.1365-2125.2001.00342.x
   PubMed Web of Science ®Google Scholar
• Clifford, D. B., Evans, S., Yang, Y., Acosta, E. P., Goodkin, K., Tashima, K. … Gulick, R. M. for the A5097s Study Team. (2005). Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Annals of Internal Medicine, 143(10), 714–721. doi: 143/10/714 [pii]. Retrieved from PM:16287792. doi: 10.7326/0003-4819-143-10-200511150-00008
   PubMed Web of Science ®Google Scholar
• Egger, M., May, M., Chene, G., Phillips, A. N., Ledergerber, B., Dabis, F., … Sterne, J. A. C. (2002). Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet, 360(9327), 119–129. doi: S0140673602094114 [pii]. Retrieved from PM:12126821. doi: 10.1016/S0140-6736(02)09411-4
   PubMed Web of Science ®Google Scholar
• Elzi, L., Erb, S., Furrer, H., Ledergerber, B., Cavassini, M., Hirschel, B. … Swiss HIV Cohort Study. (2012). Choice of initial combination antiretroviral therapy in individuals with HIV infection: Determinants and outcomes. Archives of Internal Medicine, 172(17), 1313–1321. doi:1309577 [pii];10.1001/archinternmed.2012.3216. Retrieved from PM:22892835.
   PubMed Web of Science ®Google Scholar
• Elzi, L., Marzolini, C., Furrer, H., Ledergerber, B., Cavassini, M., Hirschel, B. … Swiss HIV Cohort Study. (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1), 57–65. doi:170/1/57 [pii];10.1001/archinternmed.2009.432. Retrieved from PM:20065200.
   PubMed Web of Science ®Google Scholar
• Ford, N., Mofenson, L., Kranzer, K., Medu, L., Frigati, L., Mills, E. J., & Calmy, A. (2010). Safety of efavirenz in first-trimester of pregnancy: A systematic review and meta-analysis of outcomes from observational cohorts. AIDS, 24(10), 1461–1470. doi:10.1097/QAD.0b013e32833a2a14. Retrieved from PM:20479637.
   PubMed Web of Science ®Google Scholar
• Glass, T. R., De, G. S., Weber, R., Vernazza, P. L., Rickenbach, M., Furrer, H., … Bucher, H. C. (2006). Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 41(3), 385–392. doi:10.1097/01.qai.0000186371.95301.52;00126334-200603000-00018[pii]. Retrieved from PM:16540942.
   PubMed Web of Science ®Google Scholar
• Harrigan, P. R., Hogg, R. S., Dong, W. W., Yip, B., Wynhoven, B., Woodward, J., … Montaner, J. S. G. (2005). Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. The Journal of Infectious Diseases, 191(3), 339–347. doi:JID33123 [pii];10.1086/427192. Retrieved from PM:15633092.
   PubMed Web of Science ®Google Scholar
• Lima, V. D., Hogg, R. S., Harrigan, P. R., Moore, D., Yip, B., Wood, E., & Montaner, J. S. G. (2007). Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS, 21(6), 685–692. doi:10.1097/QAD.0b013e32802ef30c;00002030-200703300-00006 [pii]. Retrieved from PM:17413689.
   PubMed Web of Science ®Google Scholar
• May, M., Sterne, J. A., Sabin, C., Costagliola, D., Justice, A. C., Thiebaut, R. … Antiretroviral Therapy Cohort Collaboration (ART-CC). (2007). Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies. AIDS, 21(9), 1185–1197. doi:10.1097/QAD.0b013e328133f285;00002030-200705310-00012 [pii]. Retrieved from PM:17502729.
   PubMed Web of Science ®Google Scholar
• Molina, J. M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., … McGrath, D. (2010). Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(3), 323–332. doi:10.1097/QAI.0b013e3181c990bf. Retrieved from PM:20032785.
   PubMed Web of Science ®Google Scholar
• Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., & Maartens, G. (2007). Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Annals of Internal Medicine, 146(8), 564–573. doi:146/8/564 [pii]. Retrieved from PM:17438315.
   PubMed Web of Science ®Google Scholar
• Orkin, C., DeJesus, E., Khanlou, H., Stoehr, A., Supparatpinyo, K., Lathouwers, E., … Tomaka, F. (2013). Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Medicine, 14(1), 49–59. doi:10.1111/j.1468-1293.2012.01060.x. Retrieved from PM:23088336.
   PubMed Web of Science ®Google Scholar
• Panel de expertos de Gesida y Plan Nacional sobre el Sida. (2014). GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014). Enfermedades infecciosas y microbiologia clinica, 32(7), 446–442. doi:S0213-005X(14)00090-1 [pii];10.1016/j.eimc.2014.02.019. Retrieved from PM:24953253.
   PubMedGoogle Scholar
• Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., … Mellors, J. W. (2008). Class-sparing regimens for initial treatment of HIV-1 infection. New England Journal of Medicine, 358(20), 2095–2106. doi:358/20/2095 [pii];10.1056/NEJMoa074609. Retrieved from PM:18480202.
   PubMed Web of Science ®Google Scholar
• Sin, N. L., & DiMatteo, M. R. (2014). Depression treatment enhances adherence to antiretroviral therapy: A meta-analysis. Annals of Behavioral Medicine, 47(3), 259–269. doi:10.1007/s12160-013-9559-6. Retrieved from PM:24234601.
   PubMed Web of Science ®Google Scholar
• Tucker, J. S., Burnam, M. A., Sherbourne, C. D., Kung, F. Y., & Gifford, A. L. (2003). Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. The American Journal of Medicine, 114(7), 573–580. doi:S0002934303000937 [pii]. Retrieved from PM:12753881. doi: 10.1016/S0002-9343(03)00093-7
   PubMed Web of Science ®Google Scholar
• Viciana, P., Ocampo, A., Hevia, H., Palazuelos, M., & Ledesma, F. (2013). Initial antiretroviral treatment in human immunodeficiency virus-infected patients in Spain: Decisions made in relation to particular immunovirological characteristics (PERFIL-es study). Enfermedades infecciosas y microbiologia clinica, doi:S0213-005X(13)00244-9 [pii];10.1016/j.eimc.2013.08.002. Retrieved from PM:24144784.
   Google Scholar
• von Wyl, V., Yerly, S., Boni, J., Burgisser, P., Klimkait, T., Battegay, M. … Swiss HIV Cohort Study. (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: A comparison of different regimen types. Archives of Internal Medicine, 167(16), 1782–1790. doi:167/16/1782 [pii];10.1001/archinte.167.16.1782. Retrieved from PM:17846398.
   PubMed Web of Science ®Google Scholar
• Zaccarelli, M., Barracchini, A., De, L. P., Perno, C. F., Soldani, F., Liuzzi, G., … Antinori, A. (2002). Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care STDS, 16(2), 67–73. doi:10.1089/10872910252806117. Retrieved from PM:11874638.
   PubMed Web of Science ®Google Scholar